<p>Dr. Luca Richeldi discusses a trial looking at pamrevlumab, an anti-connective tissue growth factor therapy for the treatment of idiopathic pulmonary fibrosi</p>

Dr. Luca Richeldi discusses a trial looking at pamrevlumab, an anti-connective tissue growth factor therapy for the treatment of idiopathic pulmonary fibrosi

Pamrevlumab and idiopathic pulmonary fibrosis

Editors speak to the journal’s authors to explore their research and its impact on people’s health, health care, and health policy in this regular podcast.

Share Pamrevlumab and idiopathic pulmonary fibrosis

Sign up to save your podcasts

Pamrevlumab and idiopathic pulmonary fibrosis

Pamrevlumab and idiopathic pulmonary fibrosis